A 3-year study of Candida infections among patients with malignancy: etiologic agents and antifungal susceptibility profile
Frontiers in Cellular and Infection Microbiology · 2023
DOI: 10.3389/fcimb.2023.1152552 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Mahdieh Sharifi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Hauptthemen laut MEDLINE: Candidiasis, Candidemia, Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Opportunistic fungal infections by Candida species arise among cancer patients due to the weakened immune system following extensive chemotherapy. Prophylaxis with antifungal agents have developed the resistance of Candida spp. to antifungals. Accurate identification of yeasts and susceptibility patterns are main concerns that can directly effect on the treatment of patients.
Methods
Over a period of three years, 325 cancer patients suspected to Candida infections were included in the current investigation. The clinical isolates were molecularly identified by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). All strains, were examined for in vitro susceptibility to the amphotericin B, itraconazole, fluconazole, and anidulafungin according to the CLSI M27 document.
Results
Seventy-four cancer patients had Candida infections (22.7%). Candida albicans was the most common species (83.8%). Antifungal susceptibility results indicated that 100% of the Candida isolates were sensitive to amphotericin B; however, 17.6%, 9.4%, and 5.4% of clinical isolates were resistant to anidulafungin, fluconazole, and itraconazole, respectively.
Conclusion
The findings of the present work shows a warning increase in resistance to echinocandins. Since all fluconazole resistance isolates were obtained from candidemia, we recommend amphotericin B as the first line therapy for this potentially fatal infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
- Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Invasive Fungi Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
- Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
- Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Infectious Diseases, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Zitieren
APA
Sharifi, M., Badiee, P., Abastabar, M., Morovati, H., Haghani, I., Noorbakhsh, M., & Mohammadi, R. (2023). A 3-year study of Candida infections among patients with malignancy: etiologic agents and antifungal susceptibility profile. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1152552
Vancouver
Sharifi M, Badiee P, Abastabar M, Morovati H, Haghani I, Noorbakhsh M, et al. A 3-year study of Candida infections among patients with malignancy: etiologic agents and antifungal susceptibility profile. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1152552
BibTeX
@article{Sharifi2023,
author = {Sharifi, Mahdieh and Badiee, Parisa and Abastabar, Mahdi and Morovati, Hamid and Haghani, Iman and Noorbakhsh, Mahta and Mohammadi, Rasoul},
title = {A 3-year study of Candida infections among patients with malignancy: etiologic agents and antifungal susceptibility profile},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2023},
doi = {10.3389/fcimb.2023.1152552}
}
EUVIMED